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Background and context
Acute lung injury (ALI) and acute respiratory distress 
syndrome (ARDS) constitute the leading cause of death 
in pediatric and adult critical care [1]. In the United 
States alone there are approximately 190,600 cases of 
ALI/ARDS with a 40% mortality rate, amounting to 
75,000 deaths annually [2]. Signiﬁ  cant ongoing morbidity, 
including pulmonary, neuromuscular, cognitive and 
psychiatric sequelae, is seen in 50 to 70% of ALI/ARDS 
survivors, and the ﬁ   nancial burden on society is 
considerable [1,3]. Th  ere are no speciﬁ  c  therapies  for 
ALI/ARDS, and management remains supportive, focus-
ing on protective mechanical ventilation strategies [4], 
restrictive intravenous ﬂ  uid management approaches [5], 
and rescue strategies such as prone positioning [6] or 
extra  corporeal membrane oxygenation [7] for severely 
hypoxemic patients. Th  ese issues underline the need to 
consider nonconventional therapeutic approaches.
Gene therapy: opportunities in ALI/ARDS
Gene-based therapy involves the insertion of genes or 
smaller nucleic acid sequences into cells and tissues to 
replace the function of a defective gene, or to alter the 
production of a speciﬁ  c gene product, in order to treat a 
disease. Gene therapy can be classiﬁ  ed into germline and 
somatic gene therapies. Germline approaches modify the 
sperm or egg prior to fertilization and confer a stable 
heritable genetic modiﬁ  cation. Somatic gene approaches 
use gene therapy to alter the function of mature cells. 
Commonly used somatic gene therapy strategies include 
the overexpression of an existing gene and/or the 
insertion of smaller nucleic acid sequences into cells to 
alter the production of an existing gene.
ALI/ARDS may be suitable for gene-based therapies as 
it is an acute but relatively transient process [8], requiring 
short-lived gene expression, obviating the need for 
repeated therapies and reducing the risk of an adverse 
immunological response. Th  e distal lung epithelium is 
selectively accessible via the tracheal route of adminis-
tration, allowing targeting of the pulmonary epithelium 
[9]. Th   e pulmonary vasculature is also relatively accessi-
ble, as the entire cardiac output must transit this circu-
lation. Antibodies that bind antigens selectively expressed 
on the pulmonary endothelial surface can be complexed 
to gene vectors to facilitate selective targeting following 
intravenous administration [10]. It is also possible to use 
gene-based strategies to target other cells central to the 
pathogenesis of ALI/ARDS, such as leuko  cytes and 
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approaches oﬀ   er the potential to selectively target 
diﬀ  erent phases of the injury and repair process. Th  e 
potential to target speciﬁ  c aspects of the injury and repair 
processes such as epithelial–mesenchymal transition, 
ﬁ  brosis,  ﬁ   brinolysis, coagulopathy and oxidative stress 
with these approaches is also clear.
Current gene-based approaches
Gene therapy requires the delivery of genes or smaller 
nucleic acid sequences into the cell nucleus using a 
carrier or vector. Th  e vector enables the gene to over-
come barriers to entry into the cell, and to make its way 
to the nucleus to be transcribed and translated itself or to 
modulate transcription and/or translation of other genes. 
Both viral and nonviral vector systems have been 
developed (Table 1).
Viral vector-delivered gene therapy
Viral vectors are the most eﬀ  ective and eﬃ   cient way of 
getting larger nucleic acid sequences, particularly genes, 
into cells (Table 1). Th  e viral genome is modiﬁ  ed  to 
remove the parts necessary for viral replication. Th  is 
segment is then replaced with the gene of interest – 
termed a transgene – coupled to a promoter that drives 
its expression. Th  e  modiﬁ  ed genome is then encapsulated 
with viral proteins. Following delivery to the target site, 
the virus binds to the host cell, enters the cytoplasm and 
releases its payload into the nucleus (Figure 1). Th  e  size 
of trans  gene that can be used depends on the capsid size. 
A number of diﬀ  erent viral vectors have been used in 
preclinical lung injury studies to date.
Adenoviral vectors
Adenoviruses have double-stranded DNA genomes, have 
demonstrated promise in preclinical models [12,13] and 
are well tolerated at low to intermediate doses in humans 
[14,15]. Advantages include their ease of production, the 
high eﬃ   ciency at which they can infect the pulmonary 
epithelium [14,16] and that they can deliver relatively 
large transgenes. A disadvantage of adenoviruses is their 
immunogenicity, particularly in repeated doses [14]. 
Newer adenoviral vectors, in which much of the 
immuno  genicity has been removed, hold promise [17]. 
While adenovirus-mediated gene transfer in the absence 
of epithelial damage is relatively ineﬃ   cient [18], this may 
be less of a problem in ALI/ARDS that is characterized 
by widespread epithelial damage.
Adeno-associated virus vectors
Adeno-associated viruses (AAVs) are single-stranded 
DNA parvoviruses that are replication deﬁ  cient [19]. A 
substantial proportion of the human population has been 
exposed to AAVs but the clinical eﬀ  ects are unknown. 
AAV vectors have a good safety proﬁ   le, and are less 
immunogenic compared with other viruses, although 
anti  bodies do develop against AAV capsid proteins that 
can compromise repeat administration. AAV vectors can 
insert genes at a speciﬁ  c site on chromosome 19. Th  e 
packaging capacity of the virus is limited to 4.7 kb, 
restricting the size of the transgene that can be used. 
AAVs are less eﬃ   cient in transducing cells than adeno-
viral vectors. Successful AAV vector gene transfer has 
been demon  strated in multiple lung cell types including 
lung progenitor cells, in both normal and naphthalene-
induced ALI lungs [20]. AAV serotypes have speciﬁ  c 
tissue tropisms, due to diﬀ  erent capsid proteins that bind 
to speciﬁ   c cell membrane receptors. AAV-5 [21] and 
AVV-6 [22] exhibit enhanced tropism for the pulmonary 
epi  thelium [21,22]. AAVs can transduce nondividing cells 
and result in long-lived transgene expression. AAV 
vectors have been used in clinical trials in cystic ﬁ  brosis 
patients, underlining their safety proﬁ  le [23,24].
Lentivirus vectors
Th   ese RNA viruses can transfect nondividing cells such 
as mature airway epithelial cells [25]. Th   e virus stably but 
randomly integrates into the genome and expression is 
likely to last for the lifetime of the cell (~100 days). Th  e 
transgene can be transmitted post mitosis, and there is 
also a risk of tumorigenesis if the transgene integrates 
near an oncogene. Th  e development of leukemias in 
children following gene therapy for severe combined 
immunodeﬁ   ciency highlights this risk [26,27]. While 
lentiviral vectors may be useful to correct a gene deﬁ    ci-
ency associated with increased risk of ALI, the long-lived 
gene expression of lentiviral delivered genes may be more 
suitable for chronic diseases than for ALI/ARDS.
Nonviral gene-based strategies
Nonviral delivery systems, while generally less eﬃ   cient 
than viral vectors in transfecting the lung epithelium, are 
increasingly used to deliver smaller DNA/RNA molecules 
(Table 1). Strategies include the use of DNA–lipid and 
DNA–polymer complexes and naked DNA/RNA oligo-
nucleotides, such as siRNA [28], decoy oligo  nucleo  tides 
[29] and plasmid DNA [30]. Nonviral delivery systems are 
less immunogenic than viral vector-based approaches, and 
can be generated in large amounts at relatively low cost.
Plasmid transfer
Plasmid vectors are composed of closed circles of double-
stranded DNA. As naked and plasmid DNA contain no 
proteins for attachment to cellular receptors, there is no 
speciﬁ   c targeting to diﬀ  erent cell types and thus it is 
essential that the DNA is placed in close contact with the 
desired cell type. Th  ese limitations make this approach 
less relevant clinically.
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Th  e therapeutic DNA is held within a sphere of lipids, 
termed a lipoplex, or within a sphere of polymers, such as 
polyethyleneimine, termed a polyplex. Lipoplexes and 
polyplexes act to protect the DNA, facilitate binding to 
the target cell membrane and also trigger endocytosis of 
the complex into the cell, thereby enhancing gene 
expression. Th  ese systems can be modiﬁ  ed to include a 
targeting peptide for a speciﬁ  c cell type, such as airway 
epithelial cells [31]. Th   ese complexes eﬃ   ciently and safely 
transfect airway epithelial cells [31], and they have 
demonstrated promise in human studies [32].
DNA and RNA oligonucleotides
siRNAs are dsRNA molecules of 20 to 25 nucleotides that 
can regulate the expression of speciﬁ   c genes. Speciﬁ  c 
siRNAs reduce inﬂ   ammation-associated lung injury in 
Table 1. Gene therapy approaches used in preclinical ALI/ARDS models
Approach Advantages  Disadvantages  Examples
Viral vector-delivered gene therapy
  Adenoviral vectors   Relatively easily produced  Immunogenic [14]  Adenoviral transfer of genes for a surfactant
 (dsDNA  genome)  Effi   ciently transfect lung    enzyme [49], angiopoietin-1 [51], HSP-70 [52], 
    epithelium [14,16]    apolipoprotein A-1 [53], and Na+,K+-ATPase pump 
    Can deliver larger genes    [55] genes attenuate experimental ALI
    Well tolerated in lower doses [1,3]    Adenoviral delivery of IL-10 gene attenuates
        zymosan ALI at low doses, but is harmful at high 
       doses  [58]
  Adeno-associated virus   Good safety profi  le; less  Limited transgene size  AAV vector gene transfer demonstrated in multiple
  vectors (ssDNA genome)  immunogenic  Diffi   cult to produce in large  lung cell types including progenitor cells in both 
    Inherently replication defi  cient  quantities  normal lungs and following naphthalene-induced 
    AAV-5 and AAV-6 lung epithelial    ALI [20]
   tropism  [10,11]   
    Transduce nondividing cells   
    Long-lived gene expression   
    Used in clinical trials for CF [12,13]
  Lentivirus vectors   Transduce nondividing cells [25]  Oncogenesis risk due to  Lentiviral transfer of shRNA to silence CD36 gene
  (RNA genome)  Integrate stably but randomly  integration into genome  expression suppresses silica-induced lung fi  brosis 
    into the genome  [26,27]  in the rat [35]
Nonviral gene-based strategies
  Plasmid transfer (closed   Easily produced at low cost  No specifi  c cell targeting  Electroporation-mediated gene transfer of the
  dsDNA circles)    Very ineffi   cient  Na+,K+-ATPase rescues endotoxin-induced lung 
       injury  [60]
  Nonviral DNA complexes   Complexes protect DNA  Less effi   cient than viral vectors  Cationic lipid-mediated transfer of the Na+,K+-
  (lipoplexes or polyplexes)  Complexes facilitate cellular    ATPase gene ameliorated high-permeability 
    targeting [31]    pulmonary edema [59]
        Lipoplex-delivered IL-10 gene decreased
       CLP-induced ALI [61]
        Systemic cationic polyethylenimine polyplexes 
       incorporating  indoleamine-2,3-dioxygenase 
        decreased ischemia–reperfusion ALI [62]
  DNA and RNA   Easily produced at low cost  No specifi  c cell targeting  Specifi  c siRNAs reduce infl  ammation-associated
  oligonucleotides (siRNA,   Smaller molecules that can    lung injury in humans [33] and in animal models
  shRNA, decoy  easily enter cells    [28,34]
  oligonucleotides)  Target regulation of specifi  c genes    shRNA-based approaches have reduced lung injury
        in animal models [35,36]
Cell-delivered gene therapy
  Mesenchymal stem/  Systemic or intrapulmonary  Relatively expensive  MSCs expressing angiopoeitin-1 attenuate
  stromal cells  delivery    endotoxin-induced ALI [40]
    Strategy used in human    Bone marrow stem cells expressing keratinocyte 
    studies [41]    growth factor via an inducible lentivirus protects 
        against bleomycin-induced lung injury [66]
  Fibroblasts  Systemic delivery    Fibroblasts expressing angiopoeitin-1 attenuate 
    Less expensive    endotoxin induced ALI [40]
AAV, adeno-associated virus; ALI, acute lung injury; ARDS, acute respiratory distress syndrome; CF, cystic fi  brosis; CLP, cecal ligation and puncture; dsDNA, double-
stranded DNA; IL, interleukin; MSC, mesenchymal stem/stromal cell; shRNA, small hairpin RNA; siRNA, small inhibiting RNA; ssDNA, single-stranded DNA.
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single strand of RNA that, when introduced into the cell, 
is reverse transcribed and integrated into the genome, 
becoming heritable. During subsequent transcription, 
the sequence generates an oligonucleotide with a tight 
hairpin turn that is processed into siRNA. shRNAs have 
reduced lung injury in animal models [35,36]. Decoy 
oligonucleotides are double-stranded DNA molecules of 
20 to 28 nucleo  tides, which bind to speciﬁ  c transcription 
factors to reduce expression of targeted genes, and have 
been successfully used in animal models [37,38].
Cell-delivered gene therapy
An alternative approach is to use systemically delivered 
cells to deliver genes to the lung. Th   is approach has been 
used to enhance the therapeutic potential of stem cells – 
such as mesenchymal stem/stromal cells, which 
demon  strate promise in preclinical ALI/ARDS models 
[39]. Fibroblasts have also been used to successfully deliver 
genes to the lung to attenuate ALI [40]. Preliminary data 
from a clinical trial in pulmonary hypertension show that 
endothelial progenitor cells overexpressing endothelial 
nitric oxide synthase (NOS3) decrease pulmonary vascular 
resistance [41], highlighting the potential of cell-delivered 
gene therapy for ALI/ARDS.
Delivery of vector to the lung
Airway delivery
Nebulization of genetic material into the lung is eﬀ  ective 
[42], safe and well tolerated [32,43,44]. Th  e integrity of 
AAV vectors [9,43] and adenoviral virus vectors [44] are 
maintained post nebulization, as are cationic lipid vectors 
[32] and DNA and RNA oligonucleotides [45]. A number 
of gene therapy clinical trials have utilized nebulization 
Figure 1. Schematic diagram of the mechanisms involved in viral vector-mediated gene therapy. The adenoviral vector encoding a new 
gene of interest binds to a cell membrane, becoming internalized within a vesicle, is subsequently released from the vesicle and is transported 
towards the nucleus, where it releases its genetic material, which is subsequently transcribed and translated to produce the therapeutic protein. 
This image is a work of the National Institutes of Health, part of the United States Department of Health and Human Services, and is in the public 
domain.
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clear clinical beneﬁ  t to date [43,44].
Intravascular delivery
Intravascular delivery approaches target the lung endo-
thelium. Th   ese approaches have been successfully used in 
preclinical studies of cell-based gene therapies [39,40], 
and also with vectors that incorporate components such 
as antibodies to target antigens on the lung endothelium 
[10].
Barriers to eff  ective gene therapy in ARDS
Successful gene-based therapies require the delivery of 
high quantities of the gene or oligonucleotide to the 
pulmonary epithelial or endothelial surface, require 
eﬃ     cient entry into the cytoplasm of these large and 
insoluble nucleic acids, which then have to move from 
the cytoplasm into the nucleus, and activate transcription 
of its product. Multiple barriers exist that hinder this 
process, not least the natural defense mechanisms of the 
lung, and additional diﬃ   culties that exist in transducing 
the acutely injured lung (Table 2). Limitations regarding 
delivery technologies and deﬁ  ciencies in our knowledge 
regarding the optimal molecular targets also reduce the 
eﬃ   cacy of these approaches.
Pulmonary defense mechanisms
Th  e lung has evolved eﬀ  ective barriers to prevent the 
uptake of any inhaled foreign particles [46]. While 
advantageous in minimizing the potential for uptake of 
external genetic material (for example, viral DNA), these 
barriers make it more diﬃ     cult to use gene-based 
therapies in the lung. Barriers to entry of foreign genetic 
material into the lung include airway mucus and the 
epithelial lining ﬂ   uid, which traps and clears inhaled 
material. Th  e glycocalyceal barrier hinders contact with 
the cell membrane, while the tight intercellular epithelial 
junctions and limited luminal endocytosis further restrict 
entry of foreign material into the epithelial cells.
Diffi   culties transducing the injured lung
Transducing the acutely injured lung may be diﬃ   cult, 
due to the presence of pulmonary edema, consolidated or 
collapsed alveoli, and additional extracellular barriers 
such as mucus. Gene-based therapies targeted at the 
pulmonary epithelium may be less eﬀ  ective where there 
is extensive denudation of the pulmonary epithelium, as 
may occur in primary ARDS. Encouragingly, there is 
some evidence to suggest that ALI may not substantially 
impair viral gene transfer to the alveolar epithelium [47].
Limitations of vector systems
Th  e key limitation of nonviral vector approaches has 
been their lack of eﬃ   ciency in mediating gene transfer 
and transgene expression in the airway epithelium. Viral 
vectors are immunogenic, due to the protein coat of the 
viral vector, and the immune response is related to both 
vector dose and number of administrations. Th  e  potential 
to limit administration to a single dose in ALI/ARDS may 
reduce this risk. However, the development of an inﬂ  am-
ma  tory response resulting in death following adminis-
tration of a ﬁ  rst-generation adenoviral vector highlights 
the risks involved [48]. Additional limitations of viral 
vectors include transgene size, which is limited by the 
size of the capsid that encloses the viral genes.
Insights from preclinical ALI/ARDS studies
Th   e therapeutic potential of gene therapy for ALI/ARDS 
is underlined by a growing body of literature demon  strat-
ing eﬃ   cacy in relevant preclinical models. In considering 
the clinical implications of these studies, it is important 
to acknowledge that animal models of ARDS do not fully 
replicate the complex pathophysiological changes seen in 
the clinical setting. Th  is is highlighted by the fact that 
many pharmacologic strategies demonstrating consider-
able promise in preclinical studies were later proven 
ineﬀ  ective in clinical trials. Nevertheless, these studies 
provide insights into the clinical potential of these 
strategies.
Studies using viral vectors
Adenovirus-mediated transfer of a gene that enhances 
surfactant production improves lung function and 
confers resistance to Pseudomonas aeruginosa infection 
(Figure 2) [49]. Adenovirus-delivered superoxide dismutase 
and catalase genes protected against hyperoxic-induced, 
Table 2. Technical challenges to gene-based therapies for 
ALI/ARDS models
Pulmonary defense mechanisms against inhaled particles
  Airway mucus and epithelial lining fl  uid
 Glycocalyceal  barrier
  Tight intercellular epithelial junctions
  Limited endocytosis at luminal surface
Diffi   culties in transducing the acutely injured lung
  Loss of alveolar epithelium
 Pulmonary  edema
  Collapsed and/or consolidated alveoli
  Bronchial plugging by mucus and debris
Limitations of vector systems
  Imunogenicity of viral vectors particularly in repeated doses
  Limitations regarding transgene size
  Limited transfection effi   ciency of nonviral vectors
Knowledge defi  cits regarding the optimal molecular targets
ALI, acute lung injury; ARDS, acute respiratory distress syndrome.
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More recent studies have demonstrated the therapeutic 
potential of overexpression of a number of genes, includ-
ing angio  poietin-1 [51], HSP-70 [52], apolipo  protein A-1 
[53], defensin β2 [54] and the Na+,K+-ATPase pump [55]. 
In contrast, overexpression of IL-1β can directly cause 
ALI [56], while overexpression of suppressor of cytokine 
signal  ing-3 worsens immune-complex-induced ALI [57]. 
Intriguingly, intra  tracheal administration of adenoviral 
vector incor  porating IL-10, prior to zymosan-induced 
lung injury, improved survival at a lower dose but was 
ineﬀ  ective and even harmful at higher doses [58].
Studies using nonviral vectors
An early murine study demonstrated that cationic lipid-
mediated transfer of the Na+,K+-ATPase gene ameliorated 
high-permeability pulmonary edema [59]. Electroporation-
assisted gene transfer of plasmids encoding for Na+,K+-
ATPase reverses endotoxin-induced lung injury [60]. Th  e 
lipoplex-delivered IL-10 gene decreased lung and 
systemic organ injury induced by cecal ligation and 
puncture in mice [61]. Systemically administered cationic 
polyethyleni  mine polyplexes incorporating indoleamine-
2,3-dioxyge  nase transduced pulmonary endo  thelial cells 
and decreased lung ischemia–reper  fusion injury [62].
Studies using DNA and RNA oligonucleotides
NF-κB decoy oligonucleotides, incorporated into viral 
vectors, attenuate systemic sepsis-induced lung injury 
when administered intravenously (Figure 3) [37]. In animal 
models, both intratracheal [34,63] and intra  venously 
[29,64] administered siRNA successfully silence their 
target genes. shRNA-based approaches have been used to 
suppress silica-induced lung ﬁ  brosis [35] and to amelior-
ate lung ischemia–reperfusion-induced lung injury [36]. 
More recently, aerosolization of siRNA that targets 
respiratory syncytial virus viral replication was safe and 
potentially eﬀ  ective in patients post lung transplant with 
respiratory syncytial virus infection [33], clearly illus-
trating the therapeutic potential of these approaches for 
ALI/ARDS.
Figure 2. Adenovirus-mediated gene transfer enhances 
surfactant production, improves lung function and confers 
resistance to infection. Intratracheal delivery of adenovirus 
encoding a modifi  ed surfactant enzyme enhances lung production 
of surfactant, and (a) attenuated the decrement in lung elastance 
and (b) increased the survival time in mice infected with 
Pseudomonas aeruginosa. PEEP, positive end-expiratory pressure. 
Reproduced with permission from The Nature Publishing Group [49].
Figure 3. NF-κB decoy oligodeoxynucleotides prevent acute 
lung injury in mice with cecal ligation and puncture-induced 
sepsis. The animals were subjected to sham operation (control), 
sepsis (10 hours after cecal ligation and puncture (CLP)), sepsis 
with the NF-κB pharmacologic inhibitor FR260330, and sepsis with 
transfection of NF-κB decoy or its scrambled form. Transpulmonary 
fl  ux of radiolabeled albumin was used to assess changes in lung 
permeability. ***P <0.001 compared with the sham-operated 
control group. ###P <0.001 compared with the CLP group without 
treatment. Reproduced with permission from The American Society 
for Pharmacology and Experimental Therapeutics [37].
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Mei and colleagues enhanced the eﬃ   cacy of mesen  chy-
mal stem/stromal cells in endotoxin-induced ALI by trans-
ducing them to overexpress angiopoeitin-1 (Figure  4) 
[39]. Mesenchymal stem/stromal cells overexpressing 
IL-10 decreased alveolar inﬁ   ltration of CD4 and CD8 
T cells following lung ischemia–reperfusion injury [65]. 
Bone marrow stem cells expressing keratinocyte growth 
factor attenuate bleomycin-induced lung injury [66]. 
Non  stem cells can also be used to deliver genes to the 
injured lung [67]. Fibroblasts overexpressing angio-
poeitin-1 attenuate endotoxin-induced lung injury [40], 
while ﬁ   broblasts overexpressing vascular endothelial 
growth factor and endothelial nitric oxide synthase can 
attenuate or even reverse endotoxin-induced ALI [68].
Gene-based therapies for ALI/ARDS: future directions
Advances in the identiﬁ   cation of therapeutic targets, 
improvements in viral and nonviral vector technologies, 
and regulation of gene-based therapies by temporal and 
spatial targeting oﬀ   er the potential to translate the 
therapeutic promise of gene-based therapies for ALI/
ARDS to the clinical setting (Table 3).
Better viral vectors
Viral vectors remain the focus of intensive research to 
optimize their eﬃ     ciency, to minimize their 
immuno  genicity and to enhance their tissue speciﬁ  city 
[19,31,  69,  70]. Strategies to develop less immunogenic 
vectors have focused on modifying the naturally 
occurring proteins in the viral coat [71]. Much research 
has been devoted to searching and characterizing both 
naturally occurring [71] and engineered capsid variants 
from mammalian species [72]. Capsid protein modiﬁ  -
cation has also been used to enhance tissue speciﬁ  city 
[70]. Envelope protein pseudotyping involves encapsulat-
ing the modiﬁ  ed genome from one virus, such as simian 
immuno deﬁ   ci  ency virus, with envelope proteins from 
another virus, such as vesicular stomatitic virus. Th  is 
encapsu  lation can enhance the therapeutic potential of 
viral vectors, by combining the advantages of one viral 
genome (for example, bigger payload or site-speciﬁ  c 
integration) with the tissue tropism of another virus.
Better nonviral vectors
Strategies to enhance the eﬀ  ectiveness of the lipoplexes 
used to deliver plasmids and other DNA/RNA oligo-
nucleotides involve manipulation of the lipoplex lipid 
content and the use of targeting peptides. Th   e choice of 
lipid inﬂ   uences expression eﬃ   ciency  by  enhancing 
release of the genetic material within the target cell 
[73,74]. Targeting peptides increases transfection eﬃ   ci-
ency by directing the lipid to a particular cell membrane 
or cell type [31]. Physical methods of plasmid delivery 
Figure 4. Gene-based therapies may be combined with stem cells to enhance their eff  ect. Representative histologic images of lung sections 
demonstrate that modifi  cation of mesenchymal stem/stromal cells (MSCs) to overexpress angiopoeitin-1 (LPS/MSCs-pANGPT1) enhanced its 
effi   cacy in attenuating endotoxin-induced lung injury (LPS/Saline) compared with MSCs alone (LPS/MSCs) or MSCs overexpressing a nonfunctional 
gene (LPS/MSCs-pFLAG). Reproduced with permission from The Public Library of Science [39].
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gene transfer by bringing the plasmid DNA into closer 
proximity with the cell membrane and/or causing tem-
porary disruption of the cell membrane. Other physical 
methods can also be used to increase in vivo gene 
transfer, including pressurized vascular delivery, laser, 
magnetic ﬁ   elds and gene gun delivery. Th  ese systems 
enable plasmid-based gene delivery to reach eﬃ   ciencies 
close to that achieved with viral vectors.
Enhanced gene expression strategies
Successful gene therapy relies upon being able to target 
the injury site, and to control the duration and levels of 
gene expression. Modifying the transgene DNA to exclude 
nonmethylated CpG motifs, typical of bacterial DNA, 
decreases the immune response and may increase trans-
gene expression [75,76]. High-eﬃ   ciency  tissue-speciﬁ  c 
promoters may improve the eﬃ   ciency and speciﬁ  city of 
transgene expression. Lung-speciﬁ   c promoters include 
surfactant promoters [77] such as the surfactant protein 
C promoter [78], a ciliated cell-speciﬁ  c promoter FOXJ1 
[79], the cytokeratin 18 promoter [80], and the Clara cell 
10-kDa protein [78]. Promoters can also be used to target 
a speciﬁ  c phase of illness, switching on when required to 
produce an eﬀ  ect at the optimal time point.
A related approach is the development of promoters 
that allow for transfected genes to be turned on and oﬀ  . 
Currently, the tetracycline-dependent gene expression 
vector [81] is the most widely used regulated system as it 
has a good safety proﬁ   le. Tetracycline is rapidly 
metabolized and cleared from the body, making it an 
ideal drug to control gene expression. However, the 
potential for an activator such as tetracycline to modulate 
the lung injury should be borne in mind. New-generation 
transactivators, with no basal activity and increased 
sensitivity, have now been developed [82]. In an ARDS 
context, conditional regulation of gene expression by the 
combined use of a lung-speciﬁ   c promoter and the 
tetracycline-dependent gene expression system may be a 
useful approach [83].
Figure 5. Therapeutic potential of selectively targeting the pulmonary endothelium with systemically delivered gene-based therapies. 
The antioxidant enzyme catalase was conjugated with antibodies to the adhesion molecule PECAM. The anti-PECAM/catalase conjugate, but not 
a nonspecifi  c IgG/catalase conjugate, bound specifi  cally to the pulmonary endothelium, and attenuated hydrogen peroxide (H2O2) injury. (a) H2O2 
produces a severe lung injury, (b) which is not attenuated by the nonspecifi  c IgG/catalase conjugate. (c) In contrast, the anti-PECAM/catalase 
conjugate does attenuate lung injury. Reproduced with permission from the American Physiological Society [10].
Table 3. Future directions for gene-based therapies
Viral vectors
  Capsid protein modifi  cation to reduce immunogenicity [71]
  Capsid protein modifi  cation to enhance tissue specifi  city [70]
  Envelope protein pseudotyping
Nonviral vectors
  Manipulation of lipoplex lipid content to enhance cellular uptake [73,74]
  Use of targeting peptides on lipoplexes and polyplexes [31]
  Strategies to enhance gene transfer; for example, electroporation, 
  ultrasound, gene gun delivery
Gene expression strategies
  Modifying transgene DNA to eliminate bacterial motifs [75,76]
  Development of high-effi   ciency tissue-specifi  c promoters [77-80]
  Development of promoters that regulate gene expression [83]
Enhanced therapeutic targeting
  Nebulization technologies [9]
  Strategies to target the pulmonary endothelium [10]
Improved cellular uptake of vector
  Surface active agents to enhance vector spread [84]
  Reduce ubiquitination of viral capsid proteins [85]
Better therapeutic targets
  Enhancement or restoration of lung epithelial and/or endothelial cell 
 function  [86]
  Strengthening lung defense mechanisms against injury [87]
  Speeding clearance of infl  ammation and infection 
  Enhancement of the repair process following ALI/ARDS [88].
ALI, acute lung injury; ARDS, acute respiratory distress syndrome.
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An advantage of gene-based strategies is the ability to 
target speciﬁ   c cells within an organ; for example, the 
epithelial cells of the lung. Novel nebulization tech-
nologies, which facilitate the delivery of large quantities 
of undamaged vector to the distal lung, demonstrate 
considerable promise in this regard [9]. Alternative 
approaches to spatial targeting include targeting speciﬁ  c 
receptors that are plentiful on the target cell to increase 
transfection eﬃ     ciency. An interesting development in 
this regard is the targeting of systemically administered 
therapies to the pulmonary endothelium using antibodies 
to proteins expressed preferentially on these cells 
(Figure 5) [10]. In these studies, the antioxidant enzyme 
catalase was conjugated with antibodies to the adhesion 
molecule PECAM, which is widely expressed on 
pulmonary endothelial cells, and to a nonspeciﬁ  c  IgG 
antibody. Th  e anti-PECAM/catalase conjugate, but not 
the IgG/catalase conjugate, bound speciﬁ   cally to the 
pulmonary endothelium and attenuated hydrogen per-
oxide injury.
Improved cellular uptake of vector
Speciﬁ   c strategies have been developed to maximize 
uptake of vector into alveolar epithelial cells. It is possible 
to enhance lung transgene expression with the use of 
surface-active agents such as perﬂ  urocarbon,  which 
enhances the spread of vector and mixing within the 
epithelial lining ﬂ  uid [84]. Agents that reduce ubiquiti-
nation of AAV capsid proteins following endocytosis, 
such as tripeptide proteasome inhibitors, dramatically 
augment (>2,000-fold) AAV vector transduction in 
airway epithelia [85].
Better therapeutic targets
Ultimately, the success or failure of gene-based therapies 
for ALI/ARDS is likely to rest on the identiﬁ  cation of 
better gene targets. Ongoing advances in our under-
standing of the pathophysiology of ALI/ARDS continue 
to reveal novel therapeutic targets for gene-based 
approaches. Promising potential approaches include 
strate  gies to enhance or restore lung epithelial and/or 
endothelial cell function [86], to strengthen lung defense 
mechanisms against injury [87], to speed clear  ance of 
inﬂ  ammation and infection, and to enhance the repair 
process following ALI/ARDS [88].
Summary and conclusions
ALI/ARDS may be a particularly suitable disease process 
for gene-based therapies (Table 4). Th   is is supported by 
increasing evidence from relevant preclinical ARDS 
models for the eﬃ     cacy of gene-based therapies that 
enhance or restore lung epithelial and/or endothelial cell 
function, strengthen lung defense mecha  nisms against 
injury, speed resolution of inﬂ  ammation and infection, 
and enhance the repair process following ALI/ARDS. 
Despite this promising preclinical evidence, the potential 
for gene based approaches to ALI/ARDS in the clinical 
setting remains to be realized. Multiple barriers exist to 
the successful use of gene-based therapies in the lung, 
which limit the eﬃ     cacy of these approaches. Future 
research approaches should focus on overcoming these 
barriers, by developing more eﬀ  ective and less immuno-
genic vector delivery systems, developing strategies to 
focus gene expression on speciﬁ  c injury zones of the lung 
for deﬁ  ned time periods, and identifying better molecular 
targets that can take advantage of these potentially very 
powerful therapeutic approaches.
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Table 4. Key points regarding gene-based therapies for ALI/ARDS
ALI/ARDS may be amenable to gene-based therapies
Ongoing advances in our understanding of the pathophysiology of ALI/ARDS have revealed multiple therapeutic targets for gene-based approaches
Numerous gene-based approaches have demonstrated promise in relevant preclinical models
The clinical potential for gene-based approaches to ALI/ARDS remains to be realized
Multiple barriers exist to successful gene-based approaches for ALI/ARDS
A greater understanding of the molecular mechanisms underlying injury and repair in ALI/ARDS, coupled with improvements in gene-based approaches, off  er 
hope for ALI/ARDS
ALI, acute lung injury; ARDS, acute respiratory distress syndrome.
Devaney et al. Critical Care 2011, 15:224 
http://ccforum.com/content/15/3/224
Page 9 of 12References
1. Rubenfeld  GD:  Epidemiology of acute lung injury. Crit Care Med 2003, 
31(4 Suppl):S276-S284.
2.  Rubenfeld G, Caldwell E, Peabody E, Weaver J, Martin D, Neff   M, Stern E, 
Hudson L: Incidence and outcomes of acute lung injury. N Engl J Med 2005, 
353:1685-1693.
3.  Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, 
Al-Saidi F, Cooper AB, Guest CB, Mazer CD, Mehta S, Stewart TE, Barr A, Cook 
D, Slutsky AS: One-year outcomes in survivors of the acute respiratory 
distress syndrome. N Engl J Med 2003, 348:683-693.
4.  Ventilation with lower tidal volumes as compared with traditional tidal 
volumes for acute lung injury and the acute respiratory distress syndrome. 
The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000, 
342:1301-1308.
5.  Wheeler A, Bernard G, Thompson B, Schoenfeld D, Wiedemann H, 
deBoisblanc B, Connors AJ, Hite R, Harabin A: Pulmonary-artery versus 
central venous catheter to guide treatment of acute lung injury. N Engl J 
Med 2006, 354:2213-2224.
6.  Sud S, Friedrich JO, Taccone P, Polli F, Adhikari NK, Latini R, Pesenti A, Guerin C, 
Mancebo J, Curley MA, Fernandez R, Chan MC, Beuret P, Voggenreiter G, Sud 
M, Tognoni G, Gattinoni L: Prone ventilation reduces mortality in patients 
with acute respiratory failure and severe hypoxemia: systematic review 
and meta-analysis. Intensive Care Med 2010, 36:585-599.
7.  Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM, Hibbert 
CL, Truesdale A, Clemens F, Cooper N, Firmin RK, Elbourne D: Effi   cacy and 
economic assessment of conventional ventilatory support versus 
extracorporeal membrane oxygenation for severe adult respiratory failure 
(CESAR): a multicentre randomised controlled trial. Lancet 2009, 
374:1351-1363.
8.  Ware LB, Matthay MA: The acute respiratory distress syndrome. N Engl J Med 
2000, 342:1334-1349.
9.  MacLoughlin R, Higgins B, Laff  ey J, O’Brien T: Optimized aerosol delivery to a 
mechanically ventilated rodent. J Aerosol Med Pulm Drug Deliv 2009, 
22:323-332.
10.  Christofi  dou-Solomidou M, Scherpereel A, Wiewrodt R, Ng K, Sweitzer T, 
Arguiri E, Shuvaev V, Solomides CC, Albelda SM, Muzykantov VR: PECAM-
directed delivery of catalase to endothelium protects against pulmonary 
vascular oxidative stress. Am J Physiol Lung Cell Mol Physiol 2003, 
285:L283-L292.
11.  Simpson A, Wallace W, Marsden M, Govan J, Porteous D, Haslett C, Sallenave J: 
Adenoviral augmentation of elafi  n protects the lung against acute injury 
mediated by activated neutrophils and bacterial infection. J Immunol 2001, 
167:1778-1786.
12.  Katkin J, Gilbert B, Langston C, French K, Beaudet A: Aerosol delivery of a 
β-galactosidase adenoviral vector to the lungs of rodents. Human Gene 
Ther 1995, 6:985-995.
13.  Scaria A, St George J, Jiang C, Kaplan J, Wadsworth S, Gregory R: Adenovirus-
mediated persistent cystic fi  brosis transmembrane conductance regulator 
expression in mouse airway epithelium. J Virol 1998, 72:7302-7309.
14.  Harvey BG, Leopold PL, Hackett NR, Grasso TM, Williams PM, Tucker AL, Kaner 
RJ, Ferris B, Gonda I, Sweeney TD, Ramalingam R, Kovesdi I, Shak S, Crystal RG: 
Airway epithelial CFTR mRNA expression in cystic fi  brosis patients after 
repetitive administration of a recombinant adenovirus. J Clin Invest 1999, 
104:1245-1255.
15.  Crystal RG, Harvey BG, Wisnivesky JP, O’Donoghue KA, Chu KW, Maroni J, 
Muscat JC, Pippo AL, Wright CE, Kaner RJ, Leopold PL, Kessler PD, Rasmussen 
HS, Rosengart TK, Hollmann C: Analysis of risk factors for local delivery of 
low- and intermediate-dose adenovirus gene transfer vectors to 
individuals with a spectrum of comorbid conditions. Human Gene Ther 
2002, 13:65-100.
16.  Hay J, McElvaney N, Herena J, Crystal R: Modifi  cation of nasal epithelial 
potential diff  erences of individuals with cystic fi  brosis consequent to local 
administration of a normal CFTR cDNA adenovirus gene transfer vector. 
Human Gene Ther 1995, 6:1487-1496.
17.  Zuckerman JB, Robinson CB, McCoy KS, Shell R, Sferra TJ, Chirmule N, Magosin 
SA, Propert KJ, Brown-Parr EC, Hughes JV, Tazelaar J, Baker C, Goldman MJ, 
Wilson JM: A phase I study of adenovirus-mediated transfer of the human 
cystic fi  brosis transmembrane conductance regulator gene to a lung 
segment of individuals with cystic fi  brosis. Human Gene Ther 1999, 
10:2973-2985.
18.  Joseph PM, O’Sullivan BP, Lapey A, Dorkin H, Oren J, Balfour R, Perricone MA, 
Rosenberg M, Wadsworth SC, Smith AE, St George JA, Meeker DP: Aerosol 
and lobar administration of a recombinant adenovirus to individuals with 
cystic fi  brosis. I. Methods, safety, and clinical implications. Human Gene 
Ther 2001, 12:1369-1382.
19.  Büning H, Perabo L, Coutelle O, Quadt-Humme S, Hallek M: Recent 
developments in adeno-associated virus vector technology. J Gene Med 
2008, 10:717-733.
20.  Liu X, Luo M, Guo C, Yan Z, Wang Y, Lei-Butters D, Engelhardt J: Analysis of 
adeno-associated virus progenitor cell transduction in mouse lung. Mol 
Ther 2009, 17:285-293.
21.  Zabner J, Seiler M, Walters R, Kotin RM, Fulgeras W, Davidson BL, Chiorini JA: 
Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical 
surfaces of airway epithelia and facilitates gene transfer. J Virol 2000, 
74:3852-3858.
22.  Halbert CL, Allen JM, Miller AD: Adeno-associated virus type 6 (AAV6) 
vectors mediate effi   cient transduction of airway epithelial cells in mouse 
lungs compared to that of AAV2 vectors. J Virol 2001, 75:6615-6624.
23.  Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, Waltz D, Milla C, Brody 
AS, Clancy JP, Ramsey B, Hamblett N, Heald AE: Repeated adeno-associated 
virus serotype 2 aerosol-mediated cystic fi  brosis transmembrane 
regulator gene transfer to the lungs of patients with cystic fi  brosis: a 
multicenter, double-blind, placebo-controlled trial. Chest 2004, 
125:509-521.
24.  Wagner JA, Messner AH, Moran ML, Daifuku R, Kouyama K, Desch JK, Manley 
S, Norbash AM, Conrad CK, Friborg S, Reynolds T, Guggino WB, Moss RB, 
Carter BJ, Wine JJ, Flotte TR, Gardner P: Safety and biological effi   cacy of an 
adeno-associated virus vector-cystic fi  brosis transmembrane regulator 
(AAV-CFTR) in the cystic fi  brosis maxillary sinus. Laryngoscope 1999, 
109(2 Pt 1):266-274.
25.  Sinn P, Hickey M, Staber P, Dylla D, Jeff  ers S, Davidson B, Sanders D, McCray P: 
Lentivirus vectors pseudotyped with fi  loviral envelope glycoproteins 
transduce airway epithelia from the apical surface independently of folate 
receptor alpha. J Virol 2003, 77:5902-5910.
26.  Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum 
P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Deist FL, Fischer A: Gene 
therapy of human severe combined immunodefi  ciency (SCID)-X1 disease. 
Science 2000, 288:669-672.
27.  Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, 
Clappier E, Caccavelli L, Delabesse E, Beldjord K, Asnafi   V, MacIntyre E, Dal 
Cortivo L, Radford I, Brousse N, Sigaux F, Moshous D, Hauer J, Borkhardt A, 
Belohradsky BH, Wintergerst U, Velez MC, Leiva L, Sorensen R, Wulff  raat N, 
Blanche S, Bushman FD, Fischer A, Cavazzana-Calvo M: Insertional 
oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-
X1. J Clin Invest 2008, 118:3132-3142.
28.  Li T, Folkesson H: RNA interference for α-ENaC inhibits rat lung fl  uid 
absorption in vivo. Am J Physiol Lung Cell Mol Physiol 2006, 290:L649-L660.
29.  Saitoh H, Masuda T, Zhang X, Shimura S, Shirato K: Eff  ect of antisense 
oligonucleotides to nuclear factor-κB on the survival of LPS-induced ARDS 
in mouse. Exp Lung Res 2002, 28:219-231.
30.  Zhou R, Norton J, Zhang N, Dean D: Electroporation-mediated transfer of 
plasmids to the lung results in reduced TLR9 signaling and infl  ammation. 
Gene Ther 2007, 14:775-780.
31.  Tagalakis AD, McAnulty RJ, Devaney J, Bottoms SE, Wong JB, Elbs M, Writer MJ, 
Hailes HC, Tabor AB, O’Callaghan C, Jaff  e A, Hart SL: A receptor-targeted 
nanocomplex vector system optimized for respiratory gene transfer. Mol 
Ther 2008, 16:907-915.
32.  Alton EW, Stern M, Farley R, Jaff  e A, Chadwick SL, Phillips J, Davies J, Smith SN, 
Browning J, Davies MG, Hodson ME, Durham SR, Li D, Jeff  ery PK, Scallan M, 
Balfour R, Eastman SJ, Cheng SH, Smith AE, Meeker D, Geddes DM: Cationic 
lipid-mediated CFTR gene transfer to the lungs and nose of patients with 
cystic fi  brosis: a double-blind placebo-controlled trial. Lancet 1999, 
353:947-954.
33.  Zamora MR, Budev M, Rolfe M, Gottlieb J, Humar A, Devincenzo J, Vaishnaw 
A, Cehelsky J, Albert G, Nochur S, Gollob JA, Glanville AR: RNA interference 
therapy in lung transplant patients infected with respiratory syncytial 
virus. Am J Respir Crit Care Med 2011, 183:531-538.
34.  Lomas-Neira J, Chung C, Wesche D, Perl M, Ayala A: In vivo gene silencing 
(with siRNA) of pulmonary expression of MIP-2 versus KC results in 
divergent eff  ects on hemorrhage-induced, neutrophil-mediated septic 
acute lung injury. J Leukoc Biol 2005, 77:846-853.
35.  Wang X, Chen Y, Lv L, Chen J: Silencing CD36 gene expression results in the 
Devaney et al. Critical Care 2011, 15:224 
http://ccforum.com/content/15/3/224
Page 10 of 12inhibition of latent-TGF-β1 activation and suppression of silica-induced 
lung fi  brosis in the rat. Respir Res 2009, 10:36.
36.  Zhang YX, Fan H, Shi Y, Xu ST, Yuan YF, Zheng RH, Wang Q: Prevention of lung 
ischemia–reperfusion injury by short hairpin RNA-mediated caspase-3 
gene silencing. J Thorac Cardiovasc Surg 2010, 139:758-764.
37.  Matsuda N, Hattori Y, Jesmin S, Gando S: Nuclear factor-κB decoy 
oligodeoxynucleotides prevent acute lung injury in mice with cecal 
ligation and puncture-induced sepsis. Mol Pharmacol 2005, 67:1018-1025.
38.  Li Y, He B, Wang Y, Wang J: Eff  ects of intratracheal administration of nuclear 
factor-κB decoy oligodeoxynucleotides on long-term cigarette smoke-
induced lung infl  ammation and pathology in mice. Respir Res 2009, 10:79.
39.  Mei S, McCarter S, Deng Y, Parker C, Liles W, Stewart D: Prevention of LPS-
induced acute lung injury in mice by mesenchymal stem cells 
overexpressing angiopoietin 1. PLoS Med 2007, 4:e269.
40.  McCarter SD, Mei SH, Lai PF, Zhang QW, Parker CH, Suen RS, Hood RD, Zhao 
YD, Deng Y, Han RN, Dumont DJ, Stewart DJ: Cell-based angiopoietin-1 
gene therapy for acute lung injury. Am J Respir Crit Care Med 2007, 
175:1014-1026.
41.  Weiss D, Kolls J, Ortiz L, Panoskaltsis-Mortari A, Prockop D: Stem cells and cell 
therapies in lung biology and lung diseases. Proc Am Thorac Soc 2008, 
5:637-667.
42.  Leung K, Louca E, Munson K, Dutzar B, Anklesaria P, Coates A: Calculating 
expected lung deposition of aerosolized administration of AAV vector in 
human clinical studies. J Gene Med 2007, 9:10-21.
43.  Moss RB, Milla C, Colombo J, Accurso F, Zeitlin PL, Clancy JP, Spencer LT, 
Pilewski J, Waltz DA, Dorkin HL, Ferkol T, Pian M, Ramsey B, Carter BJ, Martin 
DB, Heald AE: Repeated aerosolized AAV-CFTR for treatment of cystic 
fi  brosis: a randomized placebo-controlled phase 2B trial. Human Gene Ther 
2007, 18:726-732.
44.  Perricone MA, Morris JE, Pavelka K, Plog MS, O’Sullivan BP, Joseph PM, Dorkin 
H, Lapey A, Balfour R, Meeker DP, Smith AE, Wadsworth SC, St George JA: 
Aerosol and lobar administration of a recombinant adenovirus to 
individuals with cystic fi  brosis. II. Transfection effi   ciency in airway 
epithelium. Human Gene Ther 2001, 12:1383-1394.
45.  Garbuzenko O, Saad M, Pozharov V, Reuhl K, Mainelis G, Minko T: Inhibition of 
lung tumor growth by complex pulmonary delivery of drugs with 
oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci 
U S A 2010, 107:10737-10742.
46.  Griesenbach U, Alton E, Consortium UCFGT: Gene transfer to the lung: 
lessons learned from more than 2 decades of CF gene therapy. Advanced 
Drug Deliv Rev 2009, 61:128-139.
47.  Dumasius V, Mendez M, Mutlu G, Factor P: Acute lung injury does not impair 
adenoviral-mediated gene transfer to the alveolar epithelium. Chest 2002, 
121(3 Suppl):33S-34S.
48.  Raper S, Chirmule N, Lee F, Wivel N, Bagg A, Gao G, Wilson J, Batshaw M: Fatal 
systemic infl  ammatory response syndrome in a ornithine 
transcarbamylase defi  cient patient following adenoviral gene transfer. Mol 
Genet Metab 2003, 80:148-158.
49.  Zhou J, Wu Y, Henderson F, McCoy D, Salome R, McGowan S, Mallampalli R: 
Adenoviral gene transfer of a mutant surfactant enzyme ameliorates 
pseudomonas-induced lung injury. Gene Ther 2006, 13:974-985.
50.  Danel C, Erzurum S, Prayssac P, Eissa N, Crystal R, Hervé P, Baudet B, 
Mazmanian M, Lemarchand P: Gene therapy for oxidant injury-related 
diseases: adenovirus-mediated transfer of superoxide dismutase and 
catalase cDNAs protects against hyperoxia but not against ischemia–
reperfusion lung injury. Human Gene Ther 1998, 9:1487-1496.
51. Huang  Y,  Sauthoff   H, Herscovici P, Pipiya T, Cheng J, Heitner S, Szentirmai O, 
Carter B, Hay J: Angiopoietin-1 increases survival and reduces the 
development of lung edema induced by endotoxin administration in a 
murine model of acute lung injury. Crit Care Med 2008, 36:262-267.
52.  Bromberg Z, Raj N, Goloubinoff   P, Deutschman C, Weiss Y: Enhanced 
expression of 70-kilodalton heat shock protein limits cell division in a 
sepsis-induced model of acute respiratory distress syndrome. Crit Care Med 
2008, 36:246-255.
53.  Li Y, Dong J, Wu M: Human ApoA-I overexpression diminishes LPS-induced 
systemic infl  ammation and multiple organ damage in mice. Eur J 
Pharmacol 2008, 590:417-422.
54.  Shu Q, Shi Z, Zhao Z, Chen Z, Yao H, Chen Q, Hoeft A, Stuber F, Fang X: 
Protection against Pseudomonas aeruginosa pneumonia and sepsis-
induced lung injury by overexpression of β-defensin-2 in rats. Shock 2006, 
26:365-371.
55.  Adir Y, Welch L, Dumasius V, Factor P, Sznajder J, Ridge K: Overexpression of 
the Na-K-ATPase α2-subunit improves lung liquid clearance during 
ventilation-induced lung injury. Am J Physiol Lung Cell Mol Physiol 2008, 
294:L1233-L1237.
56.  Ganter MT, Roux J, Miyazawa B, Howard M, Frank JA, Su G, Sheppard D, 
Violette SM, Weinreb PH, Horan GS, Matthay MA, Pittet JF: Interleukin-1β 
causes acute lung injury via αvβ5 and αvβ6 integrin-dependent 
mechanisms. Circ Res 2008, 102:804-812.
57.  Gao H, Hoesel L, Guo R, Rancilio N, Sarma J, Ward P: Adenoviral-mediated 
overexpression of SOCS3 enhances IgG immune complex-induced acute 
lung injury. J Immunol 2006, 177:612-620.
58. McAuliff  e P, Murday M, Efron P, Scumpia P, Ungaro R, Abouhamze A, Tannahill 
C, Hutchins B, LaFace D, Moldawer L: Dose-dependent improvements in 
outcome with adenoviral expression of interleukin-10 in a murine model 
of multisystem organ failure. Gene Ther 2006, 13:276-282.
59.  Stern M, Ulrich K, Robinson C, Copeland J, Griesenbach U, Masse C, Cheng S, 
Munkonge F, Geddes D, Berthiaume Y, Alton E: Pretreatment with cationic 
lipid-mediated transfer of the Na+K+-ATPase pump in a mouse model in 
vivo augments resolution of high permeability pulmonary oedema. Gene 
Ther 2000, 7:960-966.
60.  Mutlu G, Machado-Aranda D, Norton J, Bellmeyer A, Urich D, Zhou R, Dean D: 
Electroporation-mediated gene transfer of the Na+,K+-ATPase rescues 
endotoxin-induced lung injury. Am J Respir Crit Care Med 2007, 176:582-590.
61.  Kabay B, Kocaefe C, Baykal A, Ozden H, Baycu C, Oner Z, Ozgüç M, Sayek I: 
Interleukin-10 gene transfer: prevention of multiple organ injury in a 
murine cecal ligation and puncture model of sepsis. World J Surg 2007, 
31:105-115.
62.  Liu H, Liu L, Visner G: Nonviral gene delivery with indoleamine 
2,3-dioxygenase targeting pulmonary endothelium protects against 
ischemia-reperfusion injury. Am J Transplant 2007, 7:2291-2300.
63.  Perl M, Chung C, Lomas-Neira J, Rachel T, Biffl    W, Cioffi    W, Ayala A: Silencing 
of Fas, but not caspase-8, in lung epithelial cells ameliorates pulmonary 
apoptosis, infl  ammation, and neutrophil infl  ux after hemorrhagic shock 
and sepsis. Am J Pathol 2005, 167:1545-1559.
64.  Gao C, Li R, Huan J, Li W: Caveolin-1 siRNA increases the pulmonary 
microvascular and alveolar epithelial permeability in rats. J Trauma 2011, 
70:210-219.
65.  Manning E, Pham S, Li S, Vazquez-Padron R, Mathew J, Ruiz P, Salgar S: 
Interleukin-10 delivery via mesenchymal stem cells: a novel gene therapy 
approach to prevent lung ischemia-reperfusion injury. Human Gene Ther 
2010, 21:713-727.
66.  Aguilar S, Scotton C, McNulty K, Nye E, Stamp G, Laurent G, Bonnet D, Janes S: 
Bone marrow stem cells expressing keratinocyte growth factor via an 
inducible lentivirus protects against bleomycin-induced pulmonary 
fi  brosis. PLoS One 2009, 4:e8013.
67.  Campbell A, Zhao Y, Sandhu R, Stewart D: Cell-based gene transfer of 
vascular endothelial growth factor attenuates monocrotaline-induced 
pulmonary hypertension. Circulation 2001, 104:2242-2248.
68.  Zhao Y, Courtman D, Ng D, Robb M, Deng Y, Trogadis J, Han R, Stewart D: 
Microvascular regeneration in established pulmonary hypertension by 
angiogenic gene transfer. Am J Respir Cell Mol Biol 2006, 35:182-189.
69.  Chtarto A, Bender HU, Hanemann CO, Kemp T, Lehtonen E, Levivier M, Brotchi 
J, Velu T, Tenenbaum L: Tetracycline-inducible transgene expression 
mediated by a single AAV vector. Gene Ther 2003, 10:84-94.
70.  Meng Q, Robinson D, Jenkins R, McAnulty R, Hart S: Effi   cient transfection of 
non-proliferating human airway epithelial cells with a synthetic vector 
system. J Gene Med 2004, 6:210-221.
71.  Vandenberghe L, Wilson J, Gao G: Tailoring the AAV vector capsid for gene 
therapy. Gene Ther 2009, 16:311-319.
72.  Perabo L, Huber A, Märsch S, Hallek M, Büning H: Artifi  cial evolution with 
adeno-associated viral libraries. Comb Chem High Throughput Screen 2008, 
11:118-126.
73.  Writer M, Hurley CA, Sarkar S, Copeman DM, Wong JB, Odlyha M, Jayne 
Lawrence M, Tabor AB, McAnulty RJ, Ayazi Shamlou P, Hailes HC, Hart SL: 
Analysis and optimization of the cationic lipid component of a lipid/
peptide vector formulation for enhanced transfection in vitro and in vivo. 
J Liposome Res 2006, 16:373-389.
74.  Mustapa MF, Grosse SM, Kudsiova L, Elbs M, Raiber EA, Wong JB, Brain AP, 
Armer HE, Warley A, Keppler M, Ng T, Lawrence MJ, Hart SL, Hailes HC, Tabor 
AB: Stabilized integrin-targeting ternary LPD (lipopolyplex) vectors for 
gene delivery designed to disassemble within the target cell. Bioconjugate 
Devaney et al. Critical Care 2011, 15:224 
http://ccforum.com/content/15/3/224
Page 11 of 12Chem 2009, 20:518-532.
75.  Hyde SC, Pringle IA, Abdullah S, Lawton AE, Davies LA, Varathalingam A, 
Nunez-Alonso G, Green AM, Bazzani RP, Sumner-Jones SG, Chan M, Li H, Yew 
NS, Cheng SH, Boyd AC, Davies JC, Griesenbach U, Porteous DJ, Sheppard DN, 
Munkonge FM, Alton EW, Gill DR: CpG-free plasmids confer reduced 
infl  ammation and sustained pulmonary gene expression. Nat Biotechnol 
2008, 26:549-551.
76.  Krug A, Towarowski A, Britsch S, Rothenfusser S, Hornung V, Bals R, Giese T, 
Engelmann H, Endres S, Krieg AM, Hartmann G: Toll-like receptor expression 
reveals CpG DNA as a unique microbial stimulus for plasmacytoid 
dendritic cells which synergizes with CD40 ligand to induce high amounts 
of IL-12. Eur J Immunol 2001, 31:3026-3037.
77.  Strayer M, Guttentag S, Ballard P: Targeting type II and Clara cells for 
adenovirus-mediated gene transfer using the surfactant protein B 
promoter. Am J Respir Cell Mol Biol 1998, 18:1-11.
78.  Hendrickson B, Senadheera D, Mishra S, Bui K, Wang X, Chan B, Petersen D, 
Pepper K, Lutzko C: Development of lentiviral vectors with regulated 
respiratory epithelial expression in vivo. Am J Cell Mol Biol 2007, 37:414-423.
79.  Ostrowski L, Yin W, Diggs P, Rogers T, O’Neal W, Grubb B: Expression of CFTR 
from a ciliated cell-specifi  c promoter is ineff  ective at correcting nasal 
potential diff  erence in CF mice. Gene Ther 2007, 14:1492-1501.
80.  Koehler DR, Chow YH, Plumb J, Wen Y, Rafi  i B, Belcastro R, Haardt M, Lukacs 
GL, Post M, Tanswell AK, Hu J: A human epithelium-specifi  c vector 
optimized in rat pneumocytes for lung gene therapy. Pediatr Res 2000, 
48:184-190.
81.  Gossen M, Bujard H: Tight control of gene expression in mammalian cells 
by tetracycline-responsive promoters. Proc Natl Acad Sci U S A 1992, 
89:5547-5551.
82.  Duerr J, Gruner M, Schubert S, Haberkorn U, Bujard H, Mall M: Use of a new 
generation reverse tetracycline transactivator system for quantitative 
control of conditional gene expression in the murine lung. Am J Respir Cell 
Mol Biol 2010, 178:1245-1256.
83.  Lamartina S, Silvi L, Roscilli G, Casimiro D, Simon AJ, Davies ME, Shiver JW, 
Rinaudo CD, Zampaglione I, Fattori E, Colloca S, Gonzalez Paz O, Laufer R, 
Bujard H, Cortese R, Ciliberto G, Toniatti C: Construction of an rtTA2(s)-m2/
tts(kid)-based transcription regulatory switch that displays no basal 
activity, good inducibility, and high responsiveness to doxycycline in mice 
and non-human primates. Mol Ther 2003, 7:271-280.
84.  Weiss Y, Tazelaar J, Gehan B, Bouwman A, Christofi  dou-Solomidou M, Yu Q, Raj 
N, Deutschman C: Adenoviral vector transfection into the pulmonary 
epithelium after cecal ligation and puncture in rats. Anesthesiology 2001, 
95:974-982.
85.  Yan Z, Zak R, Luxton G, Ritchie T, Bantel-Schaal U, Engelhardt J: 
Ubiquitination of both adeno-associated virus type 2 and 5 capsid 
proteins aff  ects the transduction effi   ciency of recombinant vectors. J Virol 
2002, 76:2043-2053.
86.  Kida H, Mucenski M, Thitoff   A, Le Cras T, Park K, Ikegami M, Müller W, Whitsett 
J: GP130-STAT3 regulates epithelial cell migration and is required for repair 
of the bronchiolar epithelium. Am J Pathol 2008, 172:1542-1554.
87.  ter Horst S, Fijlstra M, Sengupta S, Walther F, Wagenaar G: Spatial and 
temporal expression of surfactant proteins in hyperoxia-induced neonatal 
rat lung injury. BMC Pulm Med 2006, 6:8.
88.  Chen G, Reddy R, Newstead M, Tateda K, Kyasapura B, Standiford T: 
Intrapulmonary TNF gene therapy reverses sepsis-induced suppression of 
lung antibacterial host defense. J Immunol 2000, 165:6496-6503.
doi:10.1186/cc10216
Cite this article as: Devaney J, et al.: Clinical Review: Gene-based therapies 
for ALI/ARDS: where are we now? Critical Care 2011, 15:224.
Devaney et al. Critical Care 2011, 15:224 
http://ccforum.com/content/15/3/224
Page 12 of 12